Merck & Co., Inc. (NYSE:MRK) to Issue $0.85 Quarterly Dividend

Merck & Co., Inc. (NYSE:MRK) announced a quarterly dividend on Tuesday, May 26th. Investors of record on Monday, June 15th will be given a dividend of 0.85 per share on Wednesday, July 8th. This represents a c) annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, June 15th.

Merck & Co., Inc. has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Merck & Co., Inc. has a payout ratio of 35.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Merck & Co., Inc. to earn $9.78 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 34.8%.

Merck & Co., Inc. Price Performance

MRK opened at $122.11 on Wednesday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a 52-week low of $75.40 and a 52-week high of $125.14. The stock has a market capitalization of $301.58 billion, a P/E ratio of 34.18, a P/E/G ratio of 2.76 and a beta of 0.18. The company’s 50-day simple moving average is $116.13 and its two-hundred day simple moving average is $110.93.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts predict that Merck & Co., Inc. will post 5.16 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.